Lamivudine in chronic hepatitis B virus

Saudi Medical Journal

Volumn 23, Issue 8, 2002, Pages 929-933

  Akbar, Hisham O ^a  

^a KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

Hepatitis B virus; Lamivudine; Liver enzymes

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS B ANTIGEN; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; LIVER ENZYME; VIRUS DNA; VITAMIN B GROUP;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; PERIPHERAL NEUROPATHY; RELAPSE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED;

EID: 0036700140     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Omata M. Treatment of chronic hepatitis B infection. N Engl J Med 1998; 339: 114-115.
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745.
3. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23: 437-455.
4. Wong DK, Cheung AM, O Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha interferon treatment in patients with hepatitis B e antigen positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-323.
5. Al-Faleh FZ. Hepatitis B infection in Saudi Arabia. Annals of Saudi Medicine 1988; 8: 474-480.
6. El-Hazmi MA. Hepatitis B virus in Saudi Arabia. J Trop Med Hyg 1989; 92: 56-61.
7. Al-Faleh FZ, Ayoola EA, Arif M, Ramia S, Al Rashed R, Al Jeffry M et al. Seroepidemiology of hepatitis B virus infection in Saudi Arabian children: A base line survey for mass vaccination against hepatitis B. J Infect 1992; 24: 197-206.
8. Shobokshi OA, Serebour FE, Skakni L. Hepatitis B surface gene mutants and their emerging role in the efficacy of HBV vaccination programs. Annals of Saudi Medicine 1999; 19: 87-92.
9. Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-68.
10. Taassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA positive (pre core mutant) chronic hepatitis B. Hepatology 1999; 29: 889-896.
11. Dienstag J, Schiff E, Wright T, Perrillo RP, Hann HW, Goodman Z et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263.
12. Laras A, Koskinas J, Avgidis K, Hadziyanis SJ. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepat 1998; 5: 241-248.
13. Hadziyanis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847-851.
14. Santantonio T, Mazzola M, Lacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long term follow-up of patients with anti-Hbe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamvudine. J Hepatol 2000; 32: 300-306.
15. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS et al. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997; 71: 9392-9398.
16. Chien RN, Liaw YF, Atkins M. Pre therapy Alanine Transaminase level as determinant for hepatitis Be antigen seroconversion during lamivudine therapy in patient with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999; 30: 770-774.
17. Zeuzem S, de Man RA, Honkoop P, Roth WK, Schalm SW, Schmidt JM. Dynamics of hepatitis B infection in vivo. J Hepatol 1997; 27: 431-436.
18. Nowak MA, Bonhoeffer S, Hill AM, Boeheme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proceedings of the National Academy of Sciences of the United States of America 1996; 93: 4398-4402.
19. Liaw YF, Leung NWY, Chang TT, Guan R, Tai DI, N KY et al. Effect of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asian Hepatitis Lamivudine study Group. Gastroenterology 2000; 119: 172-180.
20. Lau DT, Khokhar F, Doo E, Chang MG, Herion D, Park Y, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32: 828-834.
21. Atkins M, Hunt CM, Brown N, Gray F, Sanathanan L, Wossner M et al. Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients. Hepatology 1998; 28 (4 Pt 2): 319A.
22. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrell DL. Mutation in HBV RNA dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714-717.
23. Tatulli I, Francavila R, Rizzo GL, Vinciguerra V, Lerardi E, Amorouso A et al. Lamivudine and alpha-interferon in combination for precore mutant chronic hepatitis B. J Hepatol 2001; 35: 805-810.